Increased risk for hepatitis C associated with solvent use among Canadian Aboriginal injection drug users

被引:4
|
作者
Shaw, Souradet Y. [1 ,2 ]
Deering, Kathleen N. [3 ]
Jolly, Ann M. [4 ,5 ]
Wylie, John L. [2 ,6 ,7 ]
机构
[1] Univ Manitoba, Ctr Global Publ Hlth, Winnipeg, MB R3E 0T6, Canada
[2] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3E 0W3, Canada
[3] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V6T 1Z3, Canada
[4] Publ Hlth Agcy Canada, Ctr Communicable Dis & Infect Control, Ottawa, ON K1A 0K9, Canada
[5] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON K1H 8M5, Canada
[6] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0J9, Canada
[7] Manitoba Hlth, Cadham Prov Lab, Winnipeg, MB R3C 3Y1, Canada
来源
HARM REDUCTION JOURNAL | 2010年 / 7卷
基金
加拿大健康研究院;
关键词
NATIONAL EPIDEMIOLOGIC SURVEY; AMERICAN-INDIAN YOUTH; INHALANT USE; SUBSTANCE USE; UNITED-STATES; HEROIN-ADDICTS; OPIATE ADDICTS; HIV-INFECTION; ABUSE; ADOLESCENTS;
D O I
10.1186/1477-7517-7-16
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Solvent abuse is a particularly serious issue affecting Aboriginal people. Here we examine the association between solvent use and socio-demographic variables, drug-related risk factors, and pathogen prevalence in Aboriginal injection drug users (IDU) in Manitoba, Canada. Methods: Data originated from a cross-sectional survey of IDU from December 2003 to September 2004. Associations between solvent use and variables of interest were assessed by multiple logistic regression. Results: A total of 266 Aboriginal IDU were included in the analysis of which 44 self-reported recent solvent use. Hepatitis C infection was 81% in solvent-users, compared to 55% in those reporting no solvent use. In multivariable models, solvent-users were younger and more likely to be infected with hepatitis C (AOR: 3.5; 95% CI: 1.3,14.7), to have shared needles in the last six months (AOR: 2.6; 95% CI: 1.0,6.8), and to have injected talwin & Ritalin (AOR: 10.0; 95% CI: 3.8,26.3). Interpretation: High hepatitis C prevalence, even after controlling for risky injection practices, suggests that solvent users may form closed networks of higher risk even amongst an already high-risk IDU population. Understanding the social-epidemiological context of initiation and maintenance of solvent use is necessary to address the inherent inequalities encountered by this subpopulation of substance users, and may inform prevention strategies for other marginalized populations.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Risk Indicators of Depressive Symptomatology Among Injection Drug Users and Increased HIV Risk Behaviour
    Lemstra, Mark
    Rogers, Marla
    Thompson, Adam
    Moraros, John
    Buckingham, Robert
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2011, 56 (06): : 358 - 366
  • [42] PREVALENCE AND CORRELATES OF HEPATITIS C AMONG INJECTION DRUG USERS: THE SIGNIFICANCE OF DURATION OF USE, INCARCERATION, AND RACE/ETHNICITY
    Latimer, William W.
    Hedden, Sarra L.
    Moleko, Anne-Gloria
    Floyd, Leah
    Lawson, April
    Melnikov, Alexander
    Severtson, S. Geoffrey
    Cole, Kristin
    JOURNAL OF DRUG ISSUES, 2009, 39 (04) : 893 - 904
  • [43] Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco
    Hahn, JA
    Page-Shafer, K
    Lum, P
    Ochoa, K
    Moss, AR
    HEPATOLOGY, 2001, 34 (01) : 180 - 187
  • [44] Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users
    Vassilev, Z. P.
    Hagan, H.
    Lyubenoya, A.
    Tomov, N.
    Vasilev, G.
    Krasteva, D.
    Des Jarlais, D. C.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2006, 17 (09) : 621 - 626
  • [45] Treating hepatitis C in recovering injection drug users
    Sylvestre, DL
    Aron, R
    Greene, DR
    Perkins, P
    GASTROENTEROLOGY, 2001, 120 (05) : A568 - A568
  • [46] Prevention and treatment of hepatitis C in injection drug users
    Edlin, BR
    HEPATOLOGY, 2002, 36 (05) : S210 - S219
  • [47] Hepatitis C Treatment in Active Injection Drug Users
    Edlin, Brian R.
    Carden, Michael R.
    Getter, Elizabeth V.
    Talal, Andrew H.
    Aden, Brandon
    Goli, Srikanth
    Ferrando, Stephen J.
    Beeder, Ann B.
    HEPATOLOGY, 2013, 58 : 1157A - 1157A
  • [48] Treating hepatitis C in active injection drug users
    Edlin, BR
    Carden, MR
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : 2131 - 2132
  • [49] Hepatitis C virus reinfection in injection drug users
    Grebely, Jason
    Conway, Brian
    Raffa, Jesse D.
    Lai, Calvin
    Krajden, Mel
    Tyndall, Mark W.
    HEPATOLOGY, 2006, 44 (05) : 1139 - 1145
  • [50] Hepatitis C in injection drug users: It is time to treat
    Grassi, Alberto
    Ballardini, Giorgio
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (20) : 3569 - 3571